2025
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Wakelee H, Investigators O. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. Journal Of Clinical Oncology 2025, 43: 2343-2349. PMID: 40446184, DOI: 10.1200/jco-24-01681.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease-free survivalPD-L1 TCCell lung cancerOverall survivalAdjuvant chemotherapySurvival outcomesResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerTumor cellsResected non-small cell lung cancerFollow-upLung cancerFive-year survival outcomesStratified hazard ratioPlatinum-based chemotherapyStage II-IIIAPhase III trialsReport survival outcomesIntention-to-treatStratified HROpen-labelIII trialsAtezolizumabChemotherapy
2024
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Wakelee H, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Felip E. IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2024, 42: lba8035-lba8035. DOI: 10.1200/jco.2024.42.17_suppl.lba8035.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease-free survivalResected non-small cell lung cancerPD-L1Overall survivalPhase III studyITT populationResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerStage II-IIIA non-small cell lung cancerFollow-upDisease-free survival improvementDisease-free survival benefitPD-L1 TCStage II-IIIACell lung cancerIntent-to-treatAdjuvant atezolizumabOS trendIII studiesOS endpointSecondary endpointsAtezoSafety profileLung cancer
2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British Journal Of Cancer 2016, 114: 737-743. PMID: 27022826, PMCID: PMC4984865, DOI: 10.1038/bjc.2016.45.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinFemaleFluorouracilFollow-Up StudiesHumansIrinotecanLeucovorinLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrganoplatinum CompoundsOxaliplatinPancreatic NeoplasmsPeritoneal NeoplasmsPrognosisProspective StudiesSurvival RateConceptsProgression-free survivalAdvanced pancreatic cancerPhase II studyOverall survivalAdverse eventsPancreatic cancerII studyResponse rateMedian progression-free survivalMulticentre phase II studyFluorodeoxyglucose positron emission tomographyUse of FOLFIRINOXMedian overall survivalHistorical control patientsMetastatic pancreatic cancerFirst prospective studyPositron emission tomographyControl patientsMetastatic diseaseProspective studyProspective dataFOLFIRINOXLAPCEmission tomographyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply